Wilson Disease Clinical Trial
Official title:
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
The assumption is that in some of the carriers, the increase in enzymes reflects tissue damage due to excess copper. The reduction of the amount of copper absorbed will decrease excess copper in the liver, which will result in a decrease in the level of liver enzymes. Zinc causes the induction of metalothionines in the intestine, which in turn prevents absorption of copper from the digestive system. Zinc administration in Wilson's patients causes the depletion of copper deposits and constitutes one of the cornerstones in the treatment of this disease.
The research group is composed of patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04573309 -
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
|
Phase 2 | |
| Completed |
NCT03539952 -
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04884815 -
Study of UX701 Gene Transfer for the Treatment of Wilson Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
| Terminated |
NCT05047523 -
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
|
Phase 3 | |
| Completed |
NCT04526210 -
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
|
Phase 1 | |
| Completed |
NCT00004338 -
Study of Zinc for Wilson Disease
|
Phase 4 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Completed |
NCT02273596 -
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
|
Phase 2 | |
| Completed |
NCT02763215 -
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
|
||
| Recruiting |
NCT05444127 -
Oral Health and Wilson's Disease: SOMAWI
|
||
| Completed |
NCT04408300 -
Study of Retinal Vascular Parameters in Patients With Wilson's Disease
|
N/A | |
| Active, not recruiting |
NCT05783687 -
Real World Evidence Study in Subjects With Wilson's Disease
|
||
| Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
| Completed |
NCT03867526 -
Establishment of Human Cellular Disease Models for Wilson Disease
|
||
| Enrolling by invitation |
NCT03589820 -
Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure
|
N/A | |
| Completed |
NCT04526197 -
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
|
Phase 1 | |
| Not yet recruiting |
NCT06430359 -
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
|
||
| Completed |
NCT04910581 -
rTMS in Wilson Disease Dysarthria
|
N/A |